Wei Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Zhou has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Datao Liu
Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai 201210, China
151 shared publications - Dongan Yu
Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China
151 shared publications - Fei Mei
Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China
151 shared publications - Hongyuan Ren
Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China
151 shared publications - Hui Xu
Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China
151 shared publications - Huikai Zhu
Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China
151 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Structure of linker-payload complexes and conjugation process of 9MW2821.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Structure of linker-payload complexes and conjugation process of 9MW2821.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S6 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Binding affinity based on enzyme-linked immunosorbent assay.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S6 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Binding affinity based on enzyme-linked immunosorbent assay.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Toxicity profiles of 9MW2821 in cynomolgus monkeys.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Toxicity profiles of 9MW2821 in cynomolgus monkeys.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Summary of pharmacokinetics studies in 9MW2821 and enfortumab vedotin in tumor-bearing mice
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Summary of pharmacokinetics studies in 9MW2821 and enfortumab vedotin in tumor-bearing mice
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Antibody-dependent cell-mediated cytotoxicity of MW282 mAb, 9MW2821, and enfortumab vedotin (EV) measured by a cell-based reporter-gene assay.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Antibody-dependent cell-mediated cytotoxicity of MW282 mAb, 9MW2821, and enfortumab vedotin (EV) measured by a cell-based reporter-gene assay.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Nectin-4 expression levels and in vitro cytotoxicity
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Nectin-4 expression levels and in vitro cytotoxicity
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Binding affinity and kinetics based on Bio Layer Interferometry
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Binding affinity and kinetics based on Bio Layer Interferometry
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.S13 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Cynomolgus monkey body weight in safety evaluation study
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.S13 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Cynomolgus monkey body weight in safety evaluation study
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Patient information for lung cancer formalin-fixed paraffin-embedded samples
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Patient information for lung cancer formalin-fixed paraffin-embedded samples
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Patient information for prostate cancer formalin-fixed paraffin-embedded samples
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Patient information for prostate cancer formalin-fixed paraffin-embedded samples